{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:33:21Z","timestamp":1778898801840,"version":"3.51.4"},"reference-count":60,"publisher":"Rockefeller University Press","issue":"9","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000923","name":"Silicon Valley Community Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sydney Frank Foundation"},{"name":"Kimmelman Fund"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180042"],"award-info":[{"award-number":["RR180042"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["F-2027-20200401"],"award-info":[{"award-number":["F-2027-20200401"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,5]]},"abstract":"<jats:p>Disease relapse and treatment-induced immunotoxicity pose significant clinical challenges for patients with hematological cancers. Here, we reveal distinctive requirements for neutralizing TNF receptor ligands APRIL and BAFF and their receptor activity in MM and DLBCL, impacting protein translation and production in MM cells and modulating the translation efficiency of the ATM interactor (ATMIN\/ACSIZ). Therapeutically, we investigated the use of BCMA decoy receptor (sBCMA-Fc) as an inhibitor of APRIL and BAFF. While wild-type sBCMA-Fc effectively blocked APRIL signaling in MM, it lacked activity in DLBCL due to its weak BAFF binding. To expand the therapeutic utility of sBCMA-Fc, we engineered an affinity-enhanced mutant sBCMA-Fc fusion molecule (sBCMA-Fc V3) 4- and 500-fold stronger in binding to APRIL and BAFF, respectively. The mutant sBCMA-Fc V3 clone significantly enhanced antitumor activity against both MM and DLBCL. Importantly, we also demonstrated an adequate toxicity profile and on-target mechanism of action in nonhuman primate studies.<\/jats:p>","DOI":"10.1084\/jem.20220214","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T02:21:00Z","timestamp":1655518860000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma"],"prefix":"10.1084","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5848-9924","authenticated-orcid":true,"given":"Yu Rebecca","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-3371","authenticated-orcid":true,"given":"Kaushik","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-0889","authenticated-orcid":true,"given":"Can","family":"Cenik","sequence":"additional","affiliation":[{"name":"Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3908","authenticated-orcid":true,"given":"Dadi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8636-3141","authenticated-orcid":true,"given":"Kazue","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-604X","authenticated-orcid":true,"given":"Chenjun","family":"Jia","sequence":"additional","affiliation":[{"name":"ChemPartner Shanghai, Shanghai, China 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-3538","authenticated-orcid":true,"given":"Caiyun Grace","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0370","authenticated-orcid":true,"given":"Hongjuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Stanford University, Stanford, CA 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6202-6394","authenticated-orcid":true,"given":"Anh","family":"Diep","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-9013","authenticated-orcid":true,"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-178X","authenticated-orcid":true,"given":"Xin Eric","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-5353","authenticated-orcid":true,"given":"Teddy Tat Chi","family":"Yang","sequence":"additional","affiliation":[{"name":"ChemPartner Shanghai, Shanghai, China 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":true,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology), Stanford University, Stanford, CA 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-4907","authenticated-orcid":true,"given":"Parveen","family":"Abidi","sequence":"additional","affiliation":[{"name":"Department of Medicine (Hematology), Stanford University, Stanford, CA 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8332-3005","authenticated-orcid":true,"given":"Wing-sze","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-1643","authenticated-orcid":true,"given":"Albert C.","family":"Koong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1940-2750","authenticated-orcid":true,"given":"Amato J.","family":"Giaccia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 1"},{"name":"Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK 7"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"291","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2023072122504018400_bib1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging B-cell therapies in systemic lupus erythematosus","volume":"17","author":"Bag-Ozbek","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"2023072122504018400_bib2","doi-asserted-by":"publisher","first-page":"gfaa140","DOI":"10.1093\/ndt\/gfaa140.mo039","article-title":"MO039 the 24-week interim analysis results of a randomized, double-blind, placebo-controlled phase II study of atacicept in patients with IGA nephropathy and persistent proteinuria","volume":"35","author":"Barratt","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"2023072122504018400_bib3","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/s41467-018-07855-x","article-title":"The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity","volume":"9","author":"Becker","year":"2018","journal-title":"Nat. Commun."},{"key":"2023072122504018400_bib4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","article-title":"BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma","volume":"93","author":"Bolkun","year":"2014","journal-title":"Ann. Hematol."},{"key":"2023072122504018400_bib5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: Structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin. Immunol."},{"key":"2023072122504018400_bib6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0301-472x(01)00774-3","article-title":"BLyS and BLyS receptor expression in non-Hodgkin\u2019s lymphoma","volume":"30","author":"Briones","year":"2002","journal-title":"Exp. Hematol."},{"key":"2023072122504018400_bib7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.thj.6200075","article-title":"Gp130 and ras mediated signaling in human plasma cell line INA-6: A cytokine-regulated tumor model for plasmacytoma","volume":"2","author":"Burger","year":"2001","journal-title":"Hematol. J."},{"key":"2023072122504018400_bib8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023072122504018400_bib9","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2023072122504018400_bib10","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023072122504018400_bib11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20032000","article-title":"TACI and BAFF-R mediate isotype switching in B cells","volume":"201","author":"Castigli","year":"2005","journal-title":"J. Exp. Med."},{"key":"2023072122504018400_bib12","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1101\/gr.193342.115","article-title":"Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans","volume":"25","author":"Cenik","year":"2015","journal-title":"Genome Res."},{"key":"2023072122504018400_bib13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"2023072122504018400_bib14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"2023072122504018400_bib15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM195303052481003","article-title":"The precipitin test for Bence-Jones protein","volume":"248","author":"Collier","year":"1953","journal-title":"N. Engl. J. Med."},{"key":"2023072122504018400_bib16","doi-asserted-by":"publisher","first-page":"100616","DOI":"10.1016\/j.blre.2019.100616","article-title":"Treatment of relapsed multiple myeloma: Evidence-based recommendations","volume":"39","author":"Durer","year":"2020","journal-title":"Blood Rev."},{"key":"2023072122504018400_bib17","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.leukres.2012.03.012","article-title":"Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma","volume":"36","author":"Fragioudaki","year":"2012","journal-title":"Leuk. Res."},{"key":"2023072122504018400_bib18","doi-asserted-by":"publisher","first-page":"112399","DOI":"10.1016\/j.yexcr.2020.112399","article-title":"BST-2\/Tetherin is involved in BAFF-enhanced proliferation and survival via canonical NF-\u03baB signaling in neoplastic B-lymphoid cells","volume":"398","author":"Fu","year":"2021","journal-title":"Exp. Cell Res."},{"key":"2023072122504018400_bib19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jmb.2009.11.041","article-title":"Multiple novel classes of APRIL-specific receptor-blocking peptides isolated by phage display","volume":"396","author":"Gordon","year":"2010","journal-title":"J. Mol. Biol."},{"key":"2023072122504018400_bib20","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat7117","article-title":"Gut T cell-independent IgA responses to commensal bacteria require engagement of the TACI receptor on B cells","volume":"5","author":"Grasset","year":"2020","journal-title":"Sci. Immunol."},{"key":"2023072122504018400_bib21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0301-472x(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: A model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp. Hematol."},{"key":"2023072122504018400_bib22","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-\u03ba B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J. Immunol."},{"key":"2023072122504018400_bib23","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J. Biol. Chem."},{"key":"2023072122504018400_bib24","doi-asserted-by":"publisher","first-page":"a032698","DOI":"10.1101\/cshperspect.a032698","article-title":"Ribosome profiling: Global views of translation","volume":"11","author":"Ingolia","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2023072122504018400_bib25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2011.10.002","article-title":"Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes","volume":"147","author":"Ingolia","year":"2011","journal-title":"Cell"},{"key":"2023072122504018400_bib26","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1074\/jbc.M111.306019","article-title":"ATM substrate Chk2-interacting Zn2+ finger (ASCIZ) Is a bi-functional transcriptional activator and feedback sensor in the regulation of dynein light chain (DYNLL1) expression","volume":"287","author":"Jurado","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2023072122504018400_bib27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1084\/jem.20120785","article-title":"The Zinc-finger protein ASCIZ regulates B cell development via DYNLL1 and Bim","volume":"209","author":"Jurado","year":"2012","journal-title":"J. Exp. Med."},{"key":"2023072122504018400_bib28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001170","article-title":"Dual functions of ASCIZ in the DNA base damage response and pulmonary organogenesis","volume":"6","author":"Jurado","year":"2010","journal-title":"PLoS Genet."},{"key":"2023072122504018400_bib29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1172\/JCI85610","article-title":"Inhibition of the GAS6\/AXL pathway augments the efficacy of chemotherapies","volume":"127","author":"Kariolis","year":"2017","journal-title":"J. Clin. Invest."},{"key":"2023072122504018400_bib30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/978-1-4939-7865-6_11","article-title":"Analysis of global gene expression profiles","volume":"1792","author":"Kassambara","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"2023072122504018400_bib31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-\u03baB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"2023072122504018400_bib32","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/blood-2008-02-137513","article-title":"Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma","volume":"112","author":"Kuo","year":"2008","journal-title":"Blood"},{"key":"2023072122504018400_bib33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/25785826.2019.1698929","article-title":"B cells targeting therapy in the management of systemic lupus erythematosus","volume":"43","author":"Lee","year":"2020","journal-title":"Immunol. Med."},{"key":"2023072122504018400_bib34","doi-asserted-by":"publisher","first-page":"21698","DOI":"10.1038\/srep21698","article-title":"Mechanisms and consequences of ATMIN repression in hypoxic conditions: Roles for p53 and HIF-1","volume":"6","author":"Leszczynska","year":"2016","journal-title":"Sci. Rep."},{"key":"2023072122504018400_bib35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature01543","article-title":"Ligand-receptor binding revealed by the TNF family member TALL-1","volume":"423","author":"Liu","year":"2003","journal-title":"Nature"},{"key":"2023072122504018400_bib36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"2023072122504018400_bib37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1593\/neo.91960","article-title":"The rGel\/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo","volume":"12","author":"Lyu","year":"2010","journal-title":"Neoplasia"},{"key":"2023072122504018400_bib38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/s0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr. Biol."},{"key":"2023072122504018400_bib39","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/sj.emboj.7600704","article-title":"ASCIZ regulates lesion-specific Rad51 focus formation and apoptosis after methylating DNA damage","volume":"24","author":"McNees","year":"2005","journal-title":"EMBO J."},{"key":"2023072122504018400_bib40","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1158\/1078-0432.CCR-20-0482","article-title":"Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer","volume":"27","author":"Miao","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2023072122504018400_bib41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.10574","article-title":"TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines","volume":"92","author":"Moreaux","year":"2007","journal-title":"Haematologica"},{"key":"2023072122504018400_bib42","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"2023072122504018400_bib43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J. Exp. Med."},{"key":"2023072122504018400_bib44","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1093\/bioinformatics\/btaa028","article-title":"RiboFlow, RiboR and RiboPy: An ecosystem for analyzing ribosome profiling data at read length resolution","volume":"36","author":"Ozadam","year":"2020","journal-title":"Bioinformatics"},{"key":"2023072122504018400_bib45","doi-asserted-by":"publisher","first-page":"33127","DOI":"10.1074\/jbc.M305754200","article-title":"Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF","volume":"278","author":"Pelletier","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2023072122504018400_bib46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2010-06-290437","article-title":"Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-\u03baB-inducing kinase while activating both canonical and alternative nuclear factor-\u03baB pathways","volume":"117","author":"Pham","year":"2011","journal-title":"Blood"},{"key":"2023072122504018400_bib47","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2023072122504018400_bib48","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bbrc.2011.09.093","article-title":"LC8 dynein light chain (DYNLL1) binds to the C-terminal domain of ATM-interacting protein (ATMINASCIZ) and regulates its subcellular localization","volume":"414","author":"Rapali","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2023072122504018400_bib49","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol."},{"key":"2023072122504018400_bib50","doi-asserted-by":"publisher","first-page":"D213","DOI":"10.1093\/nar\/gkx997","article-title":"APPRIS 2017: Principal isoforms for multiple gene sets","volume":"46","author":"Rodriguez","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"2023072122504018400_bib51","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/sj.bjc.6605241","article-title":"Atacicept in relapsed\/refractory multiple myeloma or active Waldenstrom\u2019s macroglobulinemia: A phase I study","volume":"101","author":"Rossi","year":"2009","journal-title":"Br. J. Cancer"},{"key":"2023072122504018400_bib52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"2023072122504018400_bib53","doi-asserted-by":"publisher","first-page":"16330","DOI":"10.1074\/jbc.M115.661405","article-title":"Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties","volume":"290","author":"Schuepbach-Mallepell","year":"2015","journal-title":"J. Biol. Chem."},{"key":"2023072122504018400_bib54","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41467-018-03620-2","article-title":"BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus","volume":"9","author":"Shin","year":"2018","journal-title":"Nat. Commun."},{"key":"2023072122504018400_bib55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20440","article-title":"Belimumab in lupus nephritis: A systematic review and meta-analysis","volume":"13","author":"Shrestha","year":"2021","journal-title":"Cureus"},{"key":"2023072122504018400_bib56","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2023072122504018400_bib57","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"2023072122504018400_bib58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-021-01155-2","article-title":"Molecular subgroups of diffuse large B cell lymphoma: Biology and implications for clinical practice","volume":"24","author":"Weber","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"2023072122504018400_bib59","doi-asserted-by":"publisher","first-page":"35478","DOI":"10.1074\/jbc.M005224200","article-title":"Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS","volume":"275","author":"Wu","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2023072122504018400_bib60","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: System for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat. Immunol."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20220214\/1457084\/jem_20220214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20220214\/1457084\/jem_20220214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T18:53:48Z","timestamp":1689965628000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/219\/9\/e20220214\/213366\/Developing-high-affinity-decoy-receptors-to-treat"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,5]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20220214","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.03.442500","asserted-by":"object"}]},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"e20220214"}}